Andy Batts
Long only, value, growth, momentum

Myriad Genetics: Is The Correction An Investing Opportunity

The much hyped Supreme Court ruling in June 2013, which declared that isolated human genes are not patentable, has significantly challenged Myriad Genetics' (NASDAQ:MYGN) patent landscape. The stock has seen ~50% correction following the incident. However, I believe that the company's recent move to market Sividon Diagnostics' breast cancer test EndoPredict in Europe is a positive development. This, coupled with the company's plans to transform the entire hereditary cancer market towards myRisk platform through fiscal 2015, is expected to drive the stock higher again over the medium-term.

MYGN data by YCharts

What Went Wrong?

MYGN offers the following molecular diagnostic tests:

    BRACAnalysis: For hereditary breast and ovarian cancer COLARIS / COLARIS AP: For hereditary colon cancer MELARIS: For ...
Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details